CJC-1295 vs ipamorelin: what each does, and why they're usually stacked
Both stimulate growth hormone release. They act via different receptors and are commonly combined. Here's what each contributes, with the caveat that neither is FDA approved and both are Category 2.
CJC-1295 and ipamorelin are the two most-discussed research peptides for growth-hormone-axis stimulation in biohacker circles. They're frequently stacked because they act via complementary receptors: CJC-1295 is a GHRH analog (stimulates GH via growth-hormone-releasing hormone receptors), ipamorelin is a GHSR agonist (stimulates GH via ghrelin receptors). Hitting both systems produces larger GH pulses than either alone.
| Field | CJC-1295 | Ipamorelin |
|---|---|---|
| Brand names | Modified GRF (1-29), with or without DAC | |
| Manufacturer | Research-peptide vendors | Research-peptide vendors |
| FDA approved | Not FDA approved; Category 2 (Sep 2023) | Not FDA approved; Category 2 (Sep 2023) |
| Indication | Research use; biohacker GH-axis stimulation | Research use; biohacker GH-axis stimulation |
| Mechanism | GHRH analog — stimulates GH via GHRH receptors | Selective GHSR-1a agonist — stimulates GH via ghrelin receptors |
| Delivery | Subcutaneous (weekly with DAC, daily without) | Subcutaneous (daily or split daily) |
Frequently asked
Is the CJC-1295 + ipamorelin stack safe?
There is no Phase 3 safety data for the stack specifically at biohacker-typical doses. Chronic elevation of GH and IGF-1 in healthy adults has theoretical cancer-risk concerns (IGF-1 is pro-proliferative) that are not well-characterized in this population. The short-term tolerability of each is generally acceptable in the limited clinical exposure.
Why use the stack instead of just GH injection?
Different populations with different priorities use each. Prescription recombinant GH bypasses the body's pulsatile release mechanism and is tightly regulated; the CJC-1295 + ipamorelin stack stimulates endogenous pulsatile GH release via a less-regulated (and currently illegal under Category 2) route.
Does the stack actually produce the body-composition changes people report?
Elevated GH and IGF-1 do drive measurable effects on protein synthesis and lipolysis in clinical pharmacology studies. Whether the magnitude of effect at biohacker-typical doses translates to the body-composition changes users report is not supported by controlled human trials. Real-world reports are a mix of genuine pharmacology, placebo, diet/training co-variables, and reporting bias.
Can I legally get this stack in the US right now?
No. Both CJC-1295 and ipamorelin are FDA Category 2 as of September 2023, meaning compounding pharmacies cannot prepare them. Research-peptide vendors sell them 'for research use only' — the FDA has warned that RUO labeling is void when paired with dosing information or human-use implications. The February 2026 HHS proposal may change this status after FDA review.